Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
miptenalimab (BI 754111)
i
Other names:
BI 754111, BI754111, BI-754111
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Boehringer Ingelheim
Drug class:
LAG-3 inhibitor
Related drugs:
‹
MGD013 (5)
nivolumab/relatlimab-rmbw (4)
IBI110 (2)
MK-4280 (2)
REGN3767 (2)
FS118 (1)
BMS-986016 (1)
ABL501 (0)
CB213 (0)
EMB-02 (0)
GB266 (0)
GLS-012 (0)
HLX26 (0)
IBI-323 (0)
INCA32459 (0)
SHR-1802 (0)
Sym022 (0)
TNRX-257 (0)
ZGGS15 (0)
LBL-007 (0)
XmAb22841 (0)
TSR-033 (0)
MK-4280A (0)
LAG525 (0)
RG6139 (0)
INCAGN2385 (0)
MGD013 (5)
nivolumab/relatlimab-rmbw (4)
IBI110 (2)
MK-4280 (2)
REGN3767 (2)
FS118 (1)
BMS-986016 (1)
ABL501 (0)
CB213 (0)
EMB-02 (0)
GB266 (0)
GLS-012 (0)
HLX26 (0)
IBI-323 (0)
INCA32459 (0)
SHR-1802 (0)
Sym022 (0)
TNRX-257 (0)
ZGGS15 (0)
LBL-007 (0)
XmAb22841 (0)
TSR-033 (0)
MK-4280A (0)
LAG525 (0)
RG6139 (0)
INCAGN2385 (0)
›
Associations
News
Trials
Phase
Status
Apply
Phase
Status
Apply
A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) (NCT03964233)
Phase 1
Boehringer Ingelheim
Boehringer Ingelheim
Active, not recruiting
Phase 1
Boehringer Ingelheim
Active, not recruiting
Last update posted :
06/11/2024
Initiation :
06/11/2019
Primary completion :
09/03/2024
Completion :
05/30/2026
TP53 • MDM2
|
TP53 mutation • TP53 wild-type • TP53 amplification
|
brigimadlin (BI 907828) • ezabenlimab (BI 754091) • miptenalimab (BI 754111)
This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer (NCT03433898)
Phase 1
Boehringer Ingelheim
Boehringer Ingelheim
Completed
Phase 1
Boehringer Ingelheim
Completed
Last update posted :
07/28/2023
Initiation :
02/23/2018
Primary completion :
07/20/2023
Completion :
07/20/2023
EGFR • ALK
|
PD-L1 expression • ALK rearrangement
|
ezabenlimab (BI 754091) • miptenalimab (BI 754111)
This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. (NCT03156114)
Phase 1
Boehringer Ingelheim
Boehringer Ingelheim
Completed
Phase 1
Boehringer Ingelheim
Completed
Last update posted :
06/29/2023
Initiation :
06/13/2017
Primary completion :
03/09/2023
Completion :
06/06/2023
EGFR • ALK • TMB • MSI
|
PD-L1 expression • TMB-H • MSI-H/dMMR • PD-L1 overexpression • EGFR wild-type • ALK wild-type
|
ezabenlimab (BI 754091) • miptenalimab (BI 754111)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login